http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김영림,박지원,김성환,이길용,배정모,전윤경,임지민,류성범,정승용,박규주 대한대장항문학회 2019 Annals of Coloproctolgy Vol.35 No.5
An inflammatory myofibroblastic tumor (IMT) is a solid tumor of unknown etiology frequently affecting children and young adults and commonly affecting the lung or orbital region. We present a case involving a 41-year-old man who had an IMT combined with Mycobacterium tuberculosis infection in the retroperitoneum. He presented with only pain in the right lower abdomen without accompanying symptoms; a retroperitoneal mass was found on computed tomography. The tumor had invaded the end of the ileum and was attached to the omentum, so mass excision could not be performed. The tumor was completely excised surgically and had histological features diagnostic of an IMT. Histologic findings of the omentum were positive for Ziehl-Nielsen staining for acid-fast bacilli and for a positive polymerase chain reaction for M. tuberculosis. The patient had no apparent immune disorder. These findings made this case exceptional because IMTs, which are mostly due to atypical mycobacteria, have been found mainly in immunocompromised patients.
유전자원 특허에 관한 주요 쟁점 및 TRIPs협정의 개선방안
김영림,이양기,박지은 한국무역연구원 2020 무역연구 Vol.16 No.5
Purpose With the development of bio-technology, the market size of the bio-industy has been steadily growing, and Genetic Resouce patents are also increasing in important. TRIPs Agreement is the only binding international norm in relation to the intellectual property right of Genetic Resource patent. The purpose of this paper is to discuss a revision TRIPs Agreement regarding patent on Genetic Resource to the extent that the parties do not suffer damage. Design/Methodology/Approach We used the secondary data such as convention article, report and news article. Especially, we looked into the TRIPs Agreement and Nagoya Protocol. This is because the two agreements are representative of the norms related patent on Genetic Resource. In order to analyze the issue regarding patent on Genetic Resource, we also examined cases of dispute. Findings We propose to revise three things in relation to the patent on Genetic Resource. Three things are to place PIC(Prior Informed Consent) in TRIPs Agreement, to clear the scope of patent exclusions, and to place Exhaustion Doctrine in TRIPs Agreement. Research Implications Nagoya protocol and TRIPs Agreement has its limitations. We would like to acknowledge the limitation of each norm and revise it to a norm that is satisfactory to all parties concerned with genetic resources.
김영림,윤순정,이영일,김영지,김예지,최준식,안현경,곽동욱,한유정,이시원,김민형,정진훈,류현미,김문영,한정열 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.98 No.-
We aimed to study the pregnancy outcome of women inadvertently exposed to midazolam during the first trimester of pregnancy. In a prospective cohort study, 124 women inadvertently exposed to midazolam during the first trimester of pregnancy and an age- and gravidity-matched control group were enrolled between January 2000 and December 2011 at Korean Motherisk Prgram, a teratogen information services. Study outcomes were gestational age at birth, major congenital malformations, birth weight. Fetal outcomes were evaluated in 95 women inadvertently exposed to midazolam during the first trimester of pregnancy and in 194 control subjects. Newborns were examined at birth by neonatologist and by imaging studies if any suspicious abnormality were noted. In midazolam exposed group, pregnancy course included 95 births (76.6%), 7 spontaneous abortions (5.6%), 1 IUFD (.8%) 1 voluntary abortion (.8%), 4 ongoing pregnancy (3.2%) and 16 cases were lost to follow-up(12.9%). Pregnancy outcomes were evaluated in 103 women inadvertently to midazolam and in an age-and gravidity matched 206 control subjects. Median gestational age at exposure of midazolam was 4.2 (range: 2.0-11)weeks. There is a significant statistical difference of birth weight between exposed group and control group, 3,154±384 and 3,293±513 in respectively (p=0.02) However, there is no difference in other adverse outcomes, including spontaneous abortion, gestational age at birth, low birth weight, preterm birth.(p>0.05) There was 2 (2.1%) major congenital malformations in the exposed group and 3 (1.5%) in the control group (p=0.73) There is statistically significant lower birth weight in the midazolam exposed group than control. However, there is not associated with major congenital malformations and other adverse pregnancy outcomes after the exposure of midazolam in early pregnancy.